Quick Answer
Vor Biopharma Inc. reported Net Income of -$695.98 million for fiscal year 2025.
Vor Biopharma Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$695.98M | -495.3% |
| 2024 | -$116.91M | +0.8% |
| 2023 | -$117.86M | -28.0% |
| 2022 | -$92.09M | -33.7% |
| 2021 | -$68.90M | -59.0% |
| 2020 | -$43.34M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$812.68M | -2848.9% | +48.4% |
| June 30, 2025 | -$1.57B | -5552.7% | -4744.1% |
| March 31, 2025 | -$32.49M | -5.5% | -17.9% |
| September 30, 2024 | -$27.56M | +17.0% | +1.0% |
| June 30, 2024 | -$27.84M | +7.1% | +9.6% |
| March 31, 2024 | -$30.80M | -8.3% | +7.2% |
| September 30, 2023 | -$33.19M | -39.5% | -10.7% |
| June 30, 2023 | -$29.98M | -38.4% | -5.4% |
- Vor Biopharma Inc. showed a decrease of -495.3% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Vor Biopharma Inc.’s net income has declined by 1506.0% (from -$43.34 million to -$695.98 million).
- The most recent figure is from Vor Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: